-transparent.png){kind=logo}
Chinese hamster ovary (CHO) cells were exposed to 2-acetylaminofluorene (2-AAF) and 2-aminofluorene (2-AF), and several of their N-oxidized metabolites in order to study the mechanisms by which arylamides and arylamines produce mutations in mammalian cells. The number of mutations induced at the hypoxanthine-guanine phosphoribosyl transferase locus by each compound (mutants/10(6) CHO cells/nmol compound/ml) was estimated to be: N-acetoxy-2-AAF, 310; N-hydroxy-2-AF, 3; N-hydroxy-2-AAF (with and without hepatic S9 activation), 0.7; 2-AAF (with S9), 0.1; and 2-AF (with S9), 0.09. With each compound, DNA adducts were also identified and quantified, and in all cases the major adduct was N-(deoxyguanosin-8-yl)-2-AF. 2-AAF and N-hydroxy-2-AAF also formed minor amounts of N-(deoxyguanosin-8-yl)-2-AAF and 3-(deoxyguanosin-N2-yl)-2-AAF. The relationship between mutation induction and adduct formation for each of the derivatives was similar to that previously reported for N-hydroxy-2-AF. Inclusion of the deacetylase inhibitor, paraoxon, reduced the mutagenicity of 2-AAF, N-hydroxy-2-AAF and N-acetoxy-2-AAF, and the DNA adducts produced by N-acetoxy-2-AAF to background levels. Acetyl coenzyme A increased the mutations and CHO cytosol-mediated DNA binding of N-hydroxy-2-AAF, but did not substantially increase these responses from N-hydroxy-2-AF. N-Hydroxy-2-AAF was not detectably metabolized by CHO cells. Taken together, these data indicate that CHO cells metabolized N-acetoxy-2-AAF to a reactive derivative by N-deacetylation to N-acetoxy-2-AF, while N-hydroxy-2-AF reacted directly with DNA. The major pathway of N-hydroxy-2-AAF activation appeared to be an initial O-acetylation to N-acetoxy-2-AAF and this occurred to only a limited extent in the CHO cells. N-Hydroxy-2-AAF also seemed to form an additional unknown ester intermediate that gave rise to acetylated DNA adducts. The initial step in the activation of 2-AAF and 2-AF was an N-oxidation to N-hydroxy-2-AAF and N-hydroxy-2-AF, respectively. The limited O-acetylase activity in CHO cells appeared to contribute to the low sensitivity of these cells toward mutation induction by arylamines and arylamides.
R H Heflich, and
Z Djurić, and
Z Zhuo, and
N F Fullerton, and
D A Casciano, and
F A Beland
August 1988,
Carcinogenesis,
R H Heflich, and
Z Djurić, and
Z Zhuo, and
N F Fullerton, and
D A Casciano, and
F A Beland
April 1997,
Current opinion in lipidology,
R H Heflich, and
Z Djurić, and
Z Zhuo, and
N F Fullerton, and
D A Casciano, and
F A Beland
February 2010,
PloS one,
R H Heflich, and
Z Djurić, and
Z Zhuo, and
N F Fullerton, and
D A Casciano, and
F A Beland
October 1987,
Mutation research,
R H Heflich, and
Z Djurić, and
Z Zhuo, and
N F Fullerton, and
D A Casciano, and
F A Beland
June 1992,
Biochemistry and cell biology = Biochimie et biologie cellulaire,
R H Heflich, and
Z Djurić, and
Z Zhuo, and
N F Fullerton, and
D A Casciano, and
F A Beland
March 1995,
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
R H Heflich, and
Z Djurić, and
Z Zhuo, and
N F Fullerton, and
D A Casciano, and
F A Beland
April 1984,
Cancer letters,
R H Heflich, and
Z Djurić, and
Z Zhuo, and
N F Fullerton, and
D A Casciano, and
F A Beland
January 1998,
Mutagenesis,
R H Heflich, and
Z Djurić, and
Z Zhuo, and
N F Fullerton, and
D A Casciano, and
F A Beland
July 1981,
Molecular pharmacology,
R H Heflich, and
Z Djurić, and
Z Zhuo, and
N F Fullerton, and
D A Casciano, and
F A Beland
November 2016,
Cell systems,
